Примери за използване на Pertussis vaccine на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
For the general population, the pertussis vaccine is available to prevent the illness;
There is just overwhelming data that there's an association[between the pertussis vaccine and seizures].
Whole-cell pertussis vaccine is composed of a suspension of formalin-inactivated B. pertussis cells.
Vaccination against diphtheria,tetanus and pertussis vaccine routinely given to children since 1940.
Acellular pertussis vaccines are subunit vaccines that contain purified, inactivated components of B. pertussis cells.
Great Britain, Sweden, andJapan cut back their use of pertussis vaccine because of fears about its safety.
Several acellular pertussis vaccines have been developed for different age groups; these contain different pertussis components in varying concentrations.
Great Britain, Sweden, andJapan cut back their use of pertussis vaccine because of fears about its safety.
Pertussis vaccine for children may start to lose effect after about 5 years, and some previously immunized adolescents and adults may get a mild form of the disease.
The whooping cough at any age there is no good,so please buy with pertussis vaccine to protect against all at once.
This suggests that a second booster dose of pertussis vaccine is warranted in children aged 5-7 years who have previously been vaccinated following this particular schedule.
Three countries- Great Britain, Sweden, andJapan- cut back the use of pertussis vaccine because of fear about the vaccine. .
This suggests that a second booster dose of pertussis vaccine is warranted in children aged 5-7 years who have previously been vaccinated following this particular schedule.
Although some serious side effects can occur after a dose of DTaP(usually from the pertussis vaccine part), this rarely happens.
The whole-cell pertussis vaccine was withdrawn from the U.S. market, a decade later than from the Japanese market, because of reports of severe permanent brain damage.
In the 1970s three countries- Great Britain, Sweden, andJapan- cut back the use of pertussis vaccine because they felt the risks outweighed the benefits.
Modern vaccination schedules include diphtheria toxoid in the childhood immunization, known as diphtheria andtetanus toxoids and acellular pertussis vaccine(DTaP).
This suggests that a second booster dose of pertussis vaccine is warranted in children aged 5-7 years who have previously been vaccinated following this particular schedule.
Has suffered from a severe reaction affecting the brain(encephalopathy)within 7 days of a prior dose of a pertussis vaccine(acellular or whole cell pertussis). .
Babies don't get their first dose of pertussis vaccine until 2 months old, but those first eight weeks are a vulnerable time for newborns, especially if they become infected with pertussis. .
Vaccination with Hexyon is contraindicated if the individual has experienced an encephalopathy of unknown aetiology,occurring within 7 days following prior vaccination with a pertussis containing vaccine(whole cell or acellular pertussis vaccines).
Has had any of the following events after receiving a pertussis vaccine, as the decision to give further doses of pertussis containing vaccine will need to be carefully considered.
Pertussis vaccine should not be administered to individuals with uncontrolled neurologic disorder or uncontrolled epilepsy until treatment for the condition has been established, the condition has stabilised and the benefit clearly outweighs the risk.
As an example, when television programs challenged the safety of the pertussis vaccine, the Maryland Health Department deceived the public by blaming a new“epidemic” of whooping cough on the impact of these shows.
Vaccination with Hexacima is contraindicated if the individual has experienced an encephalopathy of unknown aetiology,occurring within 7 days following prior vaccination with a pertussis containing vaccine(whole cell or acellular pertussis vaccines).
Monovalent(one-component) pertussis vaccine developed abroad and in Russia, but so far they are not included in the daily practice of vaccination, because of the presence of the combined vaccine and a series of conditions limiting their use.
Hypersensitivity to the active substances, to any of the excipients listed in section 6.1, to trace residuals(glutaraldehyde, formaldehyde, neomycin, streptomycin andpolymyxin B), to any pertussis vaccine, or after previous administration of Hexyon or a vaccine containing the same components or constituents.
Results of long term follow-up in Sweden demonstrate that acellular pertussis vaccines are efficacious in infants when administered according to the 3 and 5 months primary vaccination schedule, with a booster dose administered at approximately 12 months.
In adolescents(11 to 18 years of age), Menveo has been evaluated in two co-administrationstudies with either Tetanus, Reduced Diphtheria and Acellular Pertussis Vaccine, Adsorbed(Tdap) alone or Tdap and Human Papillomavirus Quadrivalent(Types 6, 11, 16 and 18) Vaccine, Recombinant(HPV), both of which support the co-administration of the vaccines. .
Has had any of the following events after receiving a pertussis vaccine, as the decision to give further doses of pertussis containing vaccine will need to be carefully considered:- fever of 40°C or above within 48 hours not due to another identifiable cause.